Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam
Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022
BARDA extends cost-sharing contract to support the development of cefepime-taniborbactam in patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia (HABP/VABP)
Phase 3 clinical trial of cefepime-taniborbactam in patients with HABP/VABP scheduled to begin in 2022